scholarly journals Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort

2018 ◽  
Vol 25 (1) ◽  
pp. 32-41 ◽  
Author(s):  
Michael Saborowski ◽  
Michael Dölle ◽  
Michael P. Manns ◽  
Holger Leitolf ◽  
Steffen Zender
Keyword(s):  
High Risk ◽  
Real World ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Pcsk9 Inhibitors ◽  
Therapy Adherence ◽  
High Risk Patients ◽  
Lowering Therapy ◽  
Risk Patients

Effective Lipid-lowering Therapy in High-risk Patients

2011 ◽  
Vol 1 (111) ◽  
Author(s):  
John J.P. Kastelein ◽  
Benoit J Arsenault ◽  
Jean-Claude Tardif
Keyword(s):  
High Risk ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
High Risk Patients ◽  
Lowering Therapy ◽  
Risk Patients

scholarly journals Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice

2018 ◽  
Vol 40 (9) ◽  
pp. 1484-1495.e22 ◽  
Author(s):  
Jean Ferrières ◽  
Katherine Gorcyca ◽  
Şerban R. Iorga ◽  
David Ansell ◽  
Dylan L. Steen
Keyword(s):  
General Practice ◽  
High Risk ◽  
Goal Achievement ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
High Risk Patients ◽  
Lowering Therapy ◽  
Risk Patients

Becoming more focused therapeutic lipid patterns: results from the Hungarian MULTI GAP 2010

2011 ◽  
Vol 152 (21) ◽  
pp. 822-827 ◽  
Author(s):  
István Reiber ◽  
György Paragh ◽  
László Márk ◽  
Gyula Pados
Keyword(s):  
High Risk ◽  
Goal Attainment ◽  
Treatment Strategies ◽  
Hdl Cholesterol ◽  
High Risk Group ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Frequent Use ◽  
Risk Patients

Previous studies have found that many high-risk patients are not achieving their LDL-cholesterol goals, and many patients, despite being treated with lipid-lowering therapy, also have elevated triglycerides and/or low levels of HDL-cholesterol. Aims: Authors analyzed the treatment strategies for dyslipidemic subjects following cardiovascular events similarly to their former survey from 2008 and 2009. Methods: In the MULTI GAP (MULTI Goal Attainment Problem) 2010 trial data from standard and structured questionnaires of 2332 patients were processed. Authors analyzed the proportion of the patients reaching target levels for total cholesterol, LDL-C, HDL-C, A-C (atherogen cholesterol) and triglyceride. Results: 15% (n = 355) of the patients did not receive any lipid lowering treatment. 44% of the patients treated by specialists reached the target LDL-C level of 2.5 mmol/l. In „high risk” group target levels for HDL-C were reached by 61% of the patients, and for triglyceride by 43% of the subjects. 43% of the patients with the best compliance (>90%) reached the target LDL-C level of 2.5 mmol/l. Conclusion: There is a need for more effective lipid lowering therapy with more frequent use of higher doses of statins or combinations of lipid lowering drugs. Orv. Hetil., 2011, 152, 822–827.

scholarly journals EXPERIENCE WITH THE USE OF EVOLOCUMAB THERAPY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (IN KARELIA REPUBLIC)

2020 ◽  
pp. 42-47
Author(s):  
V. A. Korneva ◽  
T. Yu. Kuznetsova ◽  
N. N. Natal’ya N. Vezikova
Keyword(s):  
Side Effects ◽  
High Risk ◽  
Familial Hypercholesterolemia ◽  
Statistical Processing ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Pcsk9 Inhibitors ◽  
Risk Patients ◽  
History Of ◽  
Lipid Spectrum

Aim: to evaluate the efficacy and safety of the use of evolocumab in patients with familial hypercholesterolemia (FH).Materials and methods: Fifteen patients with a definite FH were treated with PCSK9 inhibitors, in 11 patients with a history of CAD. Eight patients (53.3%) received evolocumab (Repata) subcutaneously 140 mg once every 2 weeks, their average age was 51.4±2.3 years, 6 men. Lipid spectrum, ALT, AST, creatinine, glucose, Lp (a) were evaluated after 3, 6, 12 and 18 months, the ECG and the clinical picture were monitored. Evolocumab was prescribed in connection with the failure to achieve the target LDL. Before the start of therapy, 7 patients received statins, 5 statins with ezetemib, 1 patient did not receive lipid-lowering therapy due to intolerance. The target LDL levels were considered: for very high risk patients less than 1.4 mmol/L, high risk – less than 1.8 mmol/L. Statistical processing of the material was performed using STATISTICA10.0.Results: On the background of evolocumab therapy, the average level of LDL after 3 months of therapy decreased by 56.4% (from 3.9±0.3 to 1.71±0.2 mmol/L), the effect persisted after a year. All patients did not stop the therapy; there were no side effects, including local ones. Target LDL was achieved in 62.5% of patients, the average LDL level after 3 months of therapy decreased by 56.4% in patients from the initial, including the case of monotherapy with evolocumab. The Lp (a) level during therapy decreased by 30%.Conclusions: Evolocumab allows to increase the achievement of the target LDL level on 40% in FH patients; target LDL level was achieved in 62.5%. LDL decreased after 3 months by 56.4%, remaining stable with prolonged therapy. The decrease in Lp(a) reached 30%. Evolocumab therapy was characterized by high adherence and the absence of side effects.

Sign in / Sign up

Export Citation Format

Share Document